首页> 外文期刊>Journal of Renal and Hepatic Disorders >Liver Transplantation for Monogenic Metabolic Diseases Involving the Kidney
【24h】

Liver Transplantation for Monogenic Metabolic Diseases Involving the Kidney

机译:涉及肾脏的单基因代谢性疾病的肝脏移植

获取原文
       

摘要

Several metabolic monogenic diseases may be cured by liver transplantation alone (LTA) or by combined liver–kidney transplantation (CLKT) when the metabolic disease has caused end-stage renal disease. Liver transplantation may be regarded as a substitute for an injured liver or as supplying a tissue that may replace a mutant protein. Two groups of diseases should be distinguished. In the first group, the kidney tissue may be severely damaged while the liver tissue is almost normal. In this group, renal transplantation is recommended according to the degree of renal damage and liver transplantation is essential as a genetic therapy for correcting the metabolic disorder. In the second group, the liver parenchymal damage is severe. In this group, liver transplantation is essential to avoid liver failure. LTA may also avoid the progression of the renal disease; otherwise a CLKT is needed. In this review, we describe monogenic metabolic diseases involving the kidney that may have beneficial effects from LTA or CLKT. We also highlight the limitations of such procedures and the choice of alternative medical conservative treatments.
机译:当代谢性疾病引起终末期肾脏疾病时,可以通过单独的肝移植(LTA)或通过肝肾联合移植(CLKT)治愈几种代谢性单基因疾病。肝移植可被视为受损肝脏的替代品或被视为提供可替代突变蛋白的组织。应该区分两种疾病。在第一组中,肾脏组织可能严重受损,而肝组织几乎正常。在这一组中,建议根据肾损害的程度进行肾移植,而肝移植作为纠正代谢异常的基因疗法必不可少。在第二组中,肝实质损害严重。在这一组中,肝移植对于避免肝衰竭至关重要。 LTA还可以避免肾脏疾病的进展;否则需要CLKT。在这篇综述中,我们描述了涉及肾脏的单基因代谢疾病,这些疾病可能从LTA或CLKT产生有益作用。我们还强调了此类程序的局限性以及替代医学保守治疗的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号